WebinarsAccording to the WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. Also, a growing number of infections such as pneumonia, tuberculosis, gonorrhea, and salmonellae are becoming harder to treat as the antibiotics used to treat them become less effective.
In this ChaiTime, Aleks quizzed some of the most innovative biotech companies in the space from both Cambridge and Oxford who are one of the pioneers/leaders in this battle.
The panelists
Paul Finn
CEO at Oxford University Spinout, Oxford Drug Design
Ajay Mistry
CEO at AI and antibiotics discovery start-up, Oppilotech
Ken Bradley
Global Head, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)
Ankit Mahadevia
CEO of NASDAQ listed, Spero Therapeutics
